To tackle the relatively unknown topic of Hyperemesis Gravidarum (HG), Chadi invites four experts from the Hyperemesis Education & Research (HER) Foundation: Kimber MacGibbon, RN, executive director and co-founder; Aimee Brecht-Doscher, MD, adviser and long-time supporter; Kelly Ryerson, MBA, chair of the board of directors; and Marlena Fejzo, PhD, survivor of HG and research advisor. The group begins by defining HG—with respect to the traditional definition as well as the modern understanding—and its prevalence among pregnant women today. The conversation evolves into the myths and misconceptions surrounding HG, the current research landscape and funding availability, progress in identifying and sequencing an important gene, drug development updates, and a whole lot more.
Read more about the HER Foundation website: www.hyperemesis.org/
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
